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Abstract 
Investigations into the medical, epidemiological and social aspects of HIV give rise to difficult 
questions in research ethics.  The number and location of many people affected with HIV, 
combined with a lack of access to basic health care and stigma associated with the disease 
have caused significant controversies, particularly for international collaborations.  This article 
briefly surveys some of the significant ethical issues arising from biomedical research into HIV 
and highlights the regulatory mechanisms in place which aim to balance complex and 
conflicting rights and interests in this difficult field of research. 
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Introduction 
As the HIV pandemic enters its third decade, with over 38 million people infected, the demand 
for a treatment or preventive vaccine is acute.  The virus has now spread to every region of the 
world and rates of new infections are still rising dramatically in sub-Saharan Africa, Eastern 
Europe and Asia.  Over 20 million people have died of AIDS since 1981[1]. 
The effectiveness of any putative treatment or preventive measure against HIV must, of 
course, be proven through research.  To date, research in communities living with or at-risk of 
HIV infection has enabled much to be learned about preventing the spread of the virus and 
maximising quality of life for those already infected. Antiretroviral medications have provided 
a major breakthrough, although they remain available to only a fraction of those who require 
them. 
Investigations into treatments for HIV raise a broad range of issues.  Drawing on the broad 
themes of standards of care and appropriate community tailoring, this article reviews the 
significant moral problems arising from biomedical research into HIV and presents some 
suggestions for the conduct of ethical research. 
Research Ethics and HIV 
Biomedical research on HIV focuses on many different aspects of the virus, including potential 
vaccines[2], the use of microbicides to prevent infection[3], prevention of maternal-foetal 
transmission[4,5] and the preventive significance of male circumcision[6].  Undertaking this 
research is not, however, an easy task[7,8]. 
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HIV research is subject to several ‘macro’ considerations. Grady, for example, highlights the 
issue of when to move to a large-scale efficacy trial, in light of the distinct scientific uncertainty 
associated with HIV but also the public health justification for a vaccine.  She also cites the 
potential for social (as opposed to physiological) harm through research participation and the 
importance of not forgetting about behavioural interventions which can prevent HIV infection 
in the first place[9].  Schüklenk and Hogan discuss the issue of non-compliance by research 
participants and the balancing of paternalism with autonomy required to solve the 
problem[10]. Complexity is also introduced by the nature of HIV trials, often large in scale in 
international in coverage, highlighting disparities in wealth, power and infrastructure between 
researchers and participants. 
From a ‘micro’ ethical perspective, if a research proposal is to be reviewed by a UK NHS 
Research Ethics Committee, several aspects of the study should be examined before approval 
is granted[11].  These include the scientific design of the study, recruitment of participants, 
obtaining informed consent, care and protection of participants, ensuring participants’ 
confidentiality and issues relevant to the participants’ community.   
Several policy documents and guidelines guide researchers who work in the field of HIV clinical 
trials.  These include comprehensive guidelines produced by UNAIDS[12], the Council for 
International Organisations of Medical Sciences[13] and The World Medical Association [14]. 
Significant controversies in HIV research 
Between these ‘macro’ and ‘micro’ issues lies a complex and interwoven web of ethical 
conundrums, particularly affecting research in developing countries.  These various problems 
can be grouped into two classes: (1) ensuring acceptable standards of care for research 
participants; and (2) tailoring research to meet the local needs of the community where it is 
being done[15]. 
Ensuring acceptable standards of care for research participants 
Determining how participants in a research study should be treated is fundamental to the 
acceptability of any project. Two aspects of HIV research have caused particular problems: the 
use of placebo-controlled trials and continuance of care after a trial has ended. 
In the late 1990’s, controversy arose over the use of placebos in research trials.  In many of the 
countries where HIV research is done, health-care for people with the virus is virtually non-
existent.  Questions therefore arose as to whether it was acceptable for control participants to 
receive a placebo medication when an effective treatment already existed, but which was 
unavailable or unaffordable in the research region [8, 16].   
On the one hand, using placebos may lead to an ethical double-standard in which trial 
participants in the developing world are exploited through not receiving the same level of care 
as those in the West. However, this disparity may be justified by recourse to the general 
disparities in the global allocation of health care, which is not something HIV research can 
overcome[15, 17]. 
In 2000, the World Medical Association (WMA) appeared to take the former view. When re-
formulating the Declaration of Helsinki, Article 29 was added, requiring that any new method 
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should be tested against the best available treatment, suggesting it was acceptable to 
undertake a placebo-controlled trial only when there was genuine uncertainty in the 
community about what constituted the preferred treatment[14].  But in the context of the 
developing world, what constitutes the best treatment?   
In 2002, the WMA added a note of clarification to Article 29. This states a placebo-controlled 
trial may be ethically acceptable even if there is a proven therapy, if there are compelling and 
scientifically sound reasons why the use of a placebo is necessary to determine the safety or 
efficacy of a new therapeutic[14].  This recognises that were it not for the permissibility of 
placebo-controlled trials, prospective research participants in the developing world may be 
denied access to research.  However, argument on this issue is far from resolved. 
The conduct of HIV research in the developing world has also attracted criticism as to the 
standards of treatment provided to trial participants after a research project has ended[15, 18, 
19].  While an intervention may be successful during a trial (to the great benefit of all who 
received it) resource constraints often prevent the intervention remaining available after the 
trial has ended, leaving participants with no continuance of care.   
This outcome seems to breach the goal that all research projects must aim to improve the 
health of the population in which they are being carried out[20].  It may also undermine the 
process of informed consent, particularly given the vulnerability and desperation of many 
potential participants[19].  As an alternative, good-faith arrangements need to be established 
at the start of a research project, including provisions for ongoing clinical care after the project 
ends; albeit recognising the fact that this process is not always straightforward and will be 
subject to political intervention[8].  In the very least, however, it seems reasonable to claim 
that any successful trial should be used in advocacy for introducing the treatment widely; and 
researchers should not simply ‘abandon’ their study populations at the end of a project. 
Tailoring research to meet the local needs of the community 
Given that the majority of HIV infections occur in developing countries, it makes sense to 
undertake a research with these populations.  However, it is important to avoid merely 
imparting Western research practices and principles to these groups. Instead, it is vital to tailor 
the research design to the specific needs of the target community. 
The first point to consider is informed consent; and here it is important to account for the 
cultural context of a study population.  Statements to participants which may seem 
straightforward in the West may have very different connotations in the developing world.  For 
example, framing a diagnostic HIV test as a ‘benefit’ of research participation may mislead 
vulnerable groups. Further, for many potential research participants, access to a trial may be 
the only way to obtain any kind of health care, which could induce participation. Additionally, 
local understanding on the part of the research team is vital, to ensure consent mechanisms 
account for and respect local knowledge, beliefs and customs[8,18]. 
A related issue is the potential for research participants to conflate the research context with 
clinical care, or something else entirely.  If certain benefits are only available to trial 
participants, they could enter the trial under the therapeutic misconception that they will 
receive individually tailored care[8, 18].  This issue is not confined to the developing world – 
some participants in London-based HIV research projects, for example, are asylum seekers.  A 
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number of this group erroneously believe that participating in a research trial may help their 
application for asylum[21].  All trial participants should therefore be made explicitly aware that 
they are not receiving free health care or other non-research related benefits. 
Further issues arise in the context of vaccine trials.  The nature of these trials is such that 
healthy volunteers (often women) are required.  There is a danger that, without appropriate 
and full explanation, trial participants or their partners may harbour a false sense of security 
about reduced susceptibility to HIV infection[18]. By misinterpreting the safety of the vaccine 
intervention or placebo being trialled, they could end up much worse-off (infected with HIV) 
than they would have been had they not participated. 
Berkley highlights another potential problem with vaccine trials: how to care for those who 
become infected during the trial [22].  That is, should these participants be provided with the 
best possible standard of care, or merely the best care available in that community? 
Conclusion 
HIV research, particularly that undertaken in developing countries, raises a diverse and 
complex range of ethical problems.  Many of these issues are ongoing, with no agreement yet 
reached between opposing parties.  At the very least, it seems necessary that all researchers 
recognise and take into account the complex and interrelated challenges that can arise.  This 
recognition should form part of a ‘situational analysis’ of every research project, to embrace all 
local needs and sensitivities. 
While a global ethic may be unattainable, the strategies, partnerships, policies and political 
commitments that have emerged to date is laudable.  It is also important that in future 
projects researchers, governments, HIV/AIDS organisations and (perhaps most importantly) 
participants actively collaborate on research design, implementation and follow-up.  Efforts 
should focus on addressing these overlapping ethical issues and developing long-term 
solutions within a framework of global justice. 
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